(Q46851619)

English

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials

scientific article published on 17 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Mycobacterium tuberculosis

0 references

attenuated vaccine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Pere-Joan Cardona i Iglesias

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Cristina Vilaplana

object named as

Cristina Vilaplana

10

0 references

object named as

Carlos Martin

17

0 references

object named as

Vicente Ausina

11

0 references

author name string

Ainhoa Arbues

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Juan I Aguilo

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Jesus Gonzalo-Asensio

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Dessislava Marinova

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Santiago Uranga

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Eugenia Puentes

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Conchita Fernandez

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Alberto Parra

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Ann Williams

12

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Simon Clark

13

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Wladimir Malaga

14

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Christophe Guilhot

15

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Brigitte Gicquel

16

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

language of work or name

0 references

publication date

17 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

31

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

42

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

4867-4873

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

Variation in protection by BCG: implications of and for heterologous immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Genome plasticity of BCG and impact on vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Novel genome polymorphisms in BCG vaccine strains and impact on efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Has BCG attenuated to impotence?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

The Development and Impact of Tuberculosis Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

An essential role for phoP in Mycobacterium tuberculosis virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

The Mycobacterium tuberculosis phoPR operon is positively autoregulated in the virulent strain H37Rv.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

The Mycobacterium tuberculosis PhoPR two-component system regulates genes essential for virulence and complex lipid biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

The second Geneva Consensus: Recommendations for novel live TB vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Production of unmarked mutations in mycobacteria using site-specific recombination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Role of the pks15/1 gene in the biosynthesis of phenolglycolipids in the Mycobacterium tuberculosis complex. Evidence that all strains synthesize glycosylated p-hydroxybenzoic methyl esters and that strains devoid of phenolglycolipids harbor a frame

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

A new evolutionary scenario for the Mycobacterium tuberculosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

The Achilles heel of BCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.051

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.07.051

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/23965219

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46851619&oldid=2134720577"